CHARLOTTE, N.C., Sept. 13, 2011 /PRNewswire/ -- Microban recently conducted in vitro testing designed to simulate planktonic and biofilm growth on High Consistency Rubber (HCR) silicone, which is commonly used in the manufacture of urinary catheters. Urinary infections are a costly source of Hospital Acquired Infections (HAIs) and current technologies have had limited success in reducing infection rates. The new Microban® silver antimicrobial technology developed for HCR silicone by Microban Medical is engineered to meet stricter FDA guidelines. The FDA guidelines are aimed at encouraging manufacturers to adopt tougher efficacy requirements that will better correlate with decreases in patient infection rates.
Initial results for Microban® antimicrobial silver technology exceed FDA guidelines, showing greater than 5 log reductions in Proteus vulgaris, Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli versus unprotected HCR silicone. In addition, Microban microbiologists assessed the impact of Microban silver technology on biofilm formation. "The ability of antimicrobial technologies to reduce biofilm formation is critical to reducing infection rates. Biofilms are communities of bacteria that are capable of resisting antibiotic treatment and are more likely to cause recurrent infections," according to Gina Sloan, Ph.D. and Director of Microbiology at Microban. The results of the new study demonstrate that Microban silver antimicrobial technology is not only effective against planktonic bacteria, but importantly the technology also prevents the formation of biofilm on HCR silicone.
"We're very excited about the in vitro study results, Microban antimicrobial silver technology will help medical device manufacturers who are utilizing HCR silicone to meet tougher FDA standards for antimicrobials in medical devices," said Ivan Ong, Ph.D. and VP of Resea
|SOURCE Microban International, Ltd.|
Copyright©2010 PR Newswire.
All rights reserved